{"created":"2014-10-08T15:21:38+00:00","modified":"2014-10-31T01:44:18+00:00","valid":{"from":"2014-10-31T01:44:18+00:00","to":"3014-10-31T01:44:18+00:00"},"hreflang":"en","title":"Pfizer Drops $119 Billion Bid For AstraZeneca","published":"2014-05-27T11:57:00+00:00","teaser":"Pharmaceutical giant Pfizer has been circling its smaller rival for months. AstraZeneca has rejected every offer saying Pfizer undervalues the company, and that it wants to remain independent.","itags":["npr_api","316166392"],"guid":"5c42a7df-32fb-4ee9-afed-39a9486fdb92","contentencoded":"<p>It would have been the biggest deal the pharmaceutical industry has seen in more than a decade. But for now, it's off the table.</p><p>Pfizer has withdrawn its offer to buy British drug company AstraZeneca for about $119 billion.</p><p>American pharmaceutical giant Pfizer, which makes Lipitor and Viagra, has been circling its smaller rival AstraZeneca for months.</p><p>AstraZeneca, which makes Nexium and Crestor, has rejected every offer saying Pfizer undervalues the company, and that it wants to remain independent.</p><p>There were fears that jobs and research facilities in the UK would be lost.</p><p>Had the deal gone through, Pfizer could have reincorporated in Britain and taken advantage of lower taxes.</p><p>Inversions as they're called, annoy members of Congress who say they erode the U.S. corporate tax base.</p><p>Both companies face stiff competition in the future as more and more people turn to less expensive, generic drugs.  <div class=\"fullattribution\">Copyright 2014 NPR. To see more, visit <a href=\"http://www.npr.org/\">http://www.npr.org/</a>.<img src=\"http://www.google-analytics.com/__utm.gif?utmac=UA-5828686-4&utmdt=Pfizer+Drops+%24119+Billion+Bid+For+AstraZeneca&utme=8(APIKey)9(MDAyOTcwNDAwMDEyODgyMDkwMTgwNzY3YQ001)\"/></div></p>","byline":"Elizabeth Blair","audio":[{"meta":{"duration":"70"},"type":"audio/m3u","href":"http://api.npr.org/m3u/1316269206-562661.m3u?orgId=1&topicId=1006&ft=3&f=316166392"}]}